Immix Biopharma, Inc. announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site. NXC-201 will be manufactured for each individual patient using the patient?s own T cells at its cellular immunotherapy manufacturing facility in California.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.24 USD | +1.36% | +3.23% | -67.63% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-67.63% | 59.15M | |
-3.77% | 88.91B | |
+4.08% | 41.25B | |
-15.09% | 31.99B | |
+53.68% | 24.73B | |
-15.13% | 15.54B | |
-8.63% | 12.05B | |
-40.39% | 12.07B | |
+6.22% | 8.84B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- IMMX Stock
- News Immix Biopharma, Inc.
- Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site